• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OS Therapies Incorporated

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SC 13G 1 tm2422947d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    OS THERAPIES INCORPORATED

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    68764Y207

     

    (CUSIP Number)

     

    August 2, 2024

     

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     

    *               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

    Page 1 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    1.NAMES OF REPORTING PERSONS

     

    Thomas A. Satterfield, Jr.

     

    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)¨
    (b)¨

     

    3.SEC USE ONLY

     

    4.CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.SOLE VOTING POWER

     

    50,000

     

    6.SHARED VOTING POWER

     

    1,244,989

     

    7.SOLE DISPOSITIVE POWER

     

    50,000

     

    8.SHARED DISPOSITIVE POWER

     

    1,244,989

     

    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,294,989

     

    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

     

    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.20%*

     

    12.TYPE OF REPORTING PERSON

     

    IN

      

    * Based on 20,884,575 shares of common stock of the issuer outstanding as of August 14, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024.

     

    Page 2 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SCHEDULE 13G

     

    Item 1.

     

    (a)Name of Issuer:

     

    OS Therapies Incorporated

     

    (b)Address of Issuer's Principal Executive Offices:

     

    115 Pullman Crossing Road, Suite 103

    Grasonville, Maryland 21638

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Thomas A. Satterfield, Jr.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

    (c)Citizenship:

     

    Incorporated by reference from Item 4 of the Cover Page.

     

    (d)Title of Class of Securities:

     

    Incorporated by reference from the Cover Page.

     

    (e)CUSIP Number:

     

    Incorporated by reference from the Cover Page.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Incorporated by reference from Item 9 of the Cover Page.

     

    (b)Percent of class:

     

    Incorporated by reference from Item 11 of the Cover Page.

     

    Page 3 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    Incorporated by reference from Item 5 of the Cover Pages.

     

    (ii)Shared power to vote or to direct the vote

     

    Incorporated by reference from Item 6 of the Cover Pages.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 7 of the Cover Pages.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 8 of the Cover Pages.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 50,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 112,500 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 1,082,489 shares are held by Satterfield Vintage Investments, L.P. Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.’s equity, and Tomsat Investment & Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 4 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 28, 2024
      Date
       
      /s/ Thomas A. Satterfield, Jr.
      Thomas A. Satterfield, Jr.

     

     

    Get the next $OSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

      Official trailer is now live at https://youtu.be/pFaockwrROM The official trailer for "Shelter Me: The Cancer Pioneers" has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15. The newest film in the Emmy Award-winning "Shelter Me" series, ‘The Cancer Pioneers' brings viewers inside cutting-edge clinical trials where dogs with cancer are being treated with breakthrough immunotherapies, which are leading to treatments that are now extending and sav

      5/2/25 9:32:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

      Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of greater than 500 days in 5 out of 15 dogs. Data from new publication in the journal "Molecular Therapy" show OST-HER2 induces strong innate and cytotoxic immune responses beginning at the 1st dose of 3 dose regimen, that correlate with prevention of metastasis and long-term survival in dogs with resected primary osteosarcoma. Data from the same study show that short-term survivors have defective immune responses to OST-HER2 that i

      4/10/25 7:42:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

      Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of

      4/9/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Auerbach Shalom sold $81,566 worth of shares (60,012 units at $1.36) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      4/11/25 9:45:07 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Romness Paul A. acquired 225,000 shares, increasing direct ownership by 10% to 2,473,000 units (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      2/28/25 6:03:39 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom disposed of $369,000 worth of shares (225,000 units at $1.64) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      2/28/25 4:05:20 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Financials

    Live finance-specific insights

    See more
    • OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

      Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of

      4/9/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

      OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) & other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets f

      2/24/25 7:25:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate

      8/9/24 9:00:00 AM ET
      $CANF
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by OS Therapies Incorporated

      EFFECT - OS Therapies Inc (0001795091) (Filer)

      4/24/25 12:15:16 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by OS Therapies Incorporated

      EFFECT - OS Therapies Inc (0001795091) (Filer)

      4/24/25 12:15:13 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by OS Therapies Incorporated

      POS AM - OS Therapies Inc (0001795091) (Filer)

      4/21/25 4:29:53 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

      OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company's tunable ADC platform leveraging its proprietary pH-sensitive SiLinker™ silicone linker technology. Dr. Shor has 20 years of experience in leading oncology discovery programs and external R&D partnerships at large pharma (Pfizer, Wyeth) and biotech companies, with specific focus on preclinical discovery and development of sma

      8/22/24 8:00:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OS Therapies with a new price target

      Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

      4/2/25 8:01:55 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by OS Therapies Incorporated

      SC 13G - OS Therapies Inc (0001795091) (Subject)

      8/28/24 4:30:09 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care